Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Ophthalmology

Navigating Your Future: Management and Research

At a Glance

While there is no cure for Central Areolar Choroidal Dystrophy (CACD), the condition is manageable. Patients can maximize their remaining sight through low-vision rehabilitation and eccentric viewing training. Regular OCT scans are crucial to catch treatable complications like leaky blood vessels.

While there is currently no medical cure for Central Areolar Choroidal Dystrophy (CACD), the word “untreatable” is not the same as “unmanageable.” Managing CACD means shifting your focus toward maximizing the vision you have, protecting the health of your remaining retinal cells, and staying prepared for the scientific breakthroughs currently in development [1][2].

A Critical Warning About Supplements

Because CACD shares similarities with Age-Related Macular Degeneration (AMD), patients often assume they should take over-the-counter AMD supplements, such as AREDS2 formulas or high-dose Vitamin A. Do not start any vision supplements without explicit approval from your Inherited Retinal Disease (IRD) specialist. In several inherited retinal diseases, high doses of Vitamin A can increase the accumulation of a toxic byproduct called lipofuscin, which can actually accelerate vision loss rather than prevent it.

The Role of Low-Vision Rehabilitation

A low-vision specialist is a key member of your care team. Unlike a standard optometrist, they focus specifically on functional vision—how you use your eyes in daily life [1][3].

  • Magnification Tools: Specialists can prescribe high-powered optical magnifiers or electronic devices that use cameras to enlarge text and adjust contrast, making reading much easier [4][5].
  • Preferred Retinal Locus (PRL) Training: Since CACD affects the center of your vision, specialists can teach you “eccentric viewing.” This technique helps you find and use a healthy part of your side vision to look at objects, effectively training your brain to use a new “sweet spot” for seeing [6][7].
  • Technology Integration: Many modern devices have built-in accessibility features—such as voice-to-text, screen readers, and high-contrast modes—that can significantly improve your independence [8][9].

Protecting Your Retinal Health

While lifestyle changes won’t fix the underlying genetic mutation, they can help create the best possible environment for your eyes and reduce additional stress on the RPE [10][11].

  • UV Protection: Light-induced toxicity can add stress to a vulnerable retina. Wearing high-quality, UV-blocking sunglasses and a wide-brimmed hat when outdoors is a simple but vital protective measure [12][13].
  • Smoking Cessation: Smoking increases oxidative stress and inflammation in the eye, which can accelerate retinal thinning. Avoiding tobacco is one of the most impactful things you can do for your long-term eye health [11][14].
  • Antioxidant-Rich Diet: A diet rich in leafy greens (lutein and zeaxanthin) and antioxidants may help support the health of the macular pigment and protect cells from oxidative damage [10][15].

Emotional and Psychological Support

Receiving a diagnosis of a progressive blinding condition in your 30s or 40s carries a heavy emotional weight. Caring for your mental health is just as important as monitoring your eyes. Consider connecting with a counselor who specializes in chronic illness or disability. Organizations like the Foundation Fighting Blindness offer invaluable resources, support groups, and connections to a community of patients who truly understand what you are going through.

Why Ongoing Monitoring Matters

Even though there isn’t a pill or surgery for CACD today, regular check-ups with your ophthalmologist remain essential.

  • Tracking Progression: Regular OCT scans allow your doctor to document the rate of change, which is vital for your own planning and for meeting the eligibility criteria of future clinical trials [16][17].
  • Managing Complications: In rare cases, the thinning of the retina in CACD can lead to choroidal neovascularization (leaky blood vessels). If this occurs, it can cause a sudden drop in vision, but it is treatable with injections if caught early [16][18].

A Look Toward the Future

The field of genetic medicine is moving at an incredible pace. Researchers are currently using animal models, specifically “knock-in” mice that carry the same PRPH2 mutations as humans, to study exactly how the disease progresses and how to stop it [19].

  • Gene Therapy: Preclinical research is exploring ways to deliver a healthy copy of the gene or use “prime editing” to correct the mutation directly in the cells [20][21].
  • Targeting Inflammation: Other studies are looking at ways to dampen the inflammatory response and oxidative stress that lead to cell death [22][11].

By staying connected with your medical team and joining patient registries, you ensure that you are at the front of the line when these laboratory successes transition into human clinical trials.

Return to Home Page

Common questions in this guide

Should I take macular degeneration supplements for CACD?
Do not start any vision supplements like AREDS2 without your doctor's approval. In some inherited retinal diseases, high doses of Vitamin A can cause toxic byproducts to build up and actually accelerate vision loss.
How can a low-vision specialist help with CACD?
A low-vision specialist helps maximize your remaining sight for daily tasks. They can prescribe specialized magnification tools and teach you eccentric viewing, a technique to use healthy parts of your peripheral vision to read and see objects.
Why do I need ongoing eye exams if there is no cure for CACD?
Regular OCT scans track the progression of the disease and check for complications. In rare cases, CACD can lead to leaky blood vessels in the retina, which must be treated quickly with eye injections to prevent sudden, severe vision loss.
Are there any future treatments being researched for CACD?
Yes, scientists are actively researching treatments using animal models. Current preclinical studies are focusing on gene therapy, prime editing to correct PRPH2 mutations, and medications to reduce retinal inflammation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can you refer me to a low-vision specialist who can help me find the right magnifiers or electronic aids for my current vision?
  2. 2.How often should I return for OCT scans to monitor for potential complications like choroidal neovascularization?
  3. 3.Are there specific dietary supplements or antioxidant-rich foods you recommend to support my overall retinal health?
  4. 4.Are there any patient registries or natural history studies for PRPH2 or CDHR1 that I should join to be notified about future trials?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Interventions Within the Scope of Occupational Therapy Practice to Improve Performance of Daily Activities for Older Adults With Low Vision: A Systematic Review.

    Liu CJ, Chang MC

    The American journal of occupational therapy : official publication of the American Occupational Therapy Association 2020; (74(1)):7401185010p1-7401185010p18 doi:10.5014/ajot.2020.038372.

    PMID: 32078506
  2. 2

    Mapping the Outcomes of Low-Vision Rehabilitation: A Scoping Review of Interventions, Challenges, and Research Gaps.

    Ekemiri K, Adebo O, Ekemiri C, et al.

    Vision (Basel, Switzerland) 2026; (10(1)) doi:10.3390/vision10010003.

    PMID: 41562954
  3. 3

    Low vision rehabilitation in improving the quality of life for patients with impaired vision: A systematic review and meta-analysis of 52 randomized clinical trials.

    Liu J, Dong J, Chen Y, et al.

    Medicine 2021; (100(19)):e25736 doi:10.1097/MD.0000000000025736.

    PMID: 34106601
  4. 4

    The Effects of Low-Vision Rehabilitation on Reading Speed and Depression in Age Related Macular Degeneration: A Meta-Analysis.

    Hamade N, Hodge WG, Rakibuz-Zaman M, Malvankar-Mehta MS

    PloS one 2016; (11(7)):e0159254 doi:10.1371/journal.pone.0159254.

    PMID: 27414030
  5. 5

    The Effect of Magnification and Contrast on Reading Performance in Different Types of Simulated Low Vision.

    Christen M, Abegg M

    Journal of eye movement research 2016; (10(2)) doi:10.16910/jemr.10.2.5.

    PMID: 33828652
  6. 6

    Fixation Stability and Preferred Retinal Locus in Advanced Age-Related Macular Degeneration

    Altınbay D, İdil ŞA

    Turkish journal of ophthalmology 2022; (52(1)):23-29 doi:10.4274/tjo.galenos.2021.27985.

    PMID: 35196836
  7. 7

    PREFERRED RETINAL LOCUS LOCATIONS IN AGE-RELATED MACULAR DEGENERATION.

    Erbezci M, Ozturk T

    Retina (Philadelphia, Pa.) 2018; (38(12)):2372-2378 doi:10.1097/IAE.0000000000001897.

    PMID: 29065012
  8. 8

    Vision rehabilitation of patients with retinitis pigmentosa.

    Shah M, Tariq Y

    Clinical & experimental optometry 2026; (109(2)):215-220 doi:10.1080/08164622.2025.2522178.

    PMID: 40690992
  9. 9

    Current Modalities for Low Vision Rehabilitation.

    Agarwal R, Tripathi A

    Cureus 2021; (13(7)):e16561 doi:10.7759/cureus.16561.

    PMID: 34466307
  10. 10

    Modulating antioxidant systems as a therapeutic approach to retinal degeneration.

    Ren X, Léveillard T

    Redox biology 2022; (57()):102510 doi:10.1016/j.redox.2022.102510.

    PMID: 36274523
  11. 11

    Cellular and molecular alterations in neurons and glial cells in inherited retinal degeneration.

    Martínez-Gil N, Maneu V, Kutsyr O, et al.

    Frontiers in neuroanatomy 2022; (16()):984052 doi:10.3389/fnana.2022.984052.

    PMID: 36225228
  12. 12

    Light as a Mediator of Acute and Chronic Retina Degeneration.

    Guarascio R, Cheetham ME

    Advances in experimental medicine and biology 2025; (1468()):247-251 doi:10.1007/978-3-031-76550-6_41.

    PMID: 39930204
  13. 13

    The endoplasmic reticulum: Homeostasis and crosstalk in retinal health and disease.

    Zhang SX, Wang JJ, Starr CR, et al.

    Progress in retinal and eye research 2024; (98()):101231 doi:10.1016/j.preteyeres.2023.101231.

    PMID: 38092262
  14. 14

    Retinal Inflammation, Cell Death and Inherited Retinal Dystrophies.

    Olivares-González L, Velasco S, Campillo I, Rodrigo R

    International journal of molecular sciences 2021; (22(4)) doi:10.3390/ijms22042096.

    PMID: 33672611
  15. 15

    Oxidative Stress as a Main Contributor of Retinal Degenerative Diseases.

    Pinilla I, Maneu V

    Antioxidants (Basel, Switzerland) 2022; (11(6)) doi:10.3390/antiox11061190.

    PMID: 35740087
  16. 16

    MULTIMODAL RETINAL IMAGING REVEALS NEW PATHOGENIC INSIGHTS IN CENTRAL AREOLAR CHOROIDAL DYSTROPHY: A CASE SERIES.

    Romano F, Cozzi E, Boon CJF, et al.

    Retinal cases & brief reports 2024; (18(1)):32-38 doi:10.1097/ICB.0000000000001325.

    PMID: 36731070
  17. 17

    Retinal Dystrophies Associated With Peripherin-2: Genetic Spectrum and Novel Clinical Observations in 241 Patients.

    Heath Jeffery RC, Thompson JA, Lo J, et al.

    Investigative ophthalmology & visual science 2024; (65(5)):22 doi:10.1167/iovs.65.5.22.

    PMID: 38743414
  18. 18

    Multimodal Study of PRPH2 Gene-Related Retinal Phenotypes.

    Antonelli G, Parravano M, Barbano L, et al.

    Diagnostics (Basel, Switzerland) 2022; (12(8)) doi:10.3390/diagnostics12081851.

    PMID: 36010202
  19. 19

    Prph2 knock-in mice recapitulate human central areolar choroidal dystrophy retinal degeneration and exhibit aberrant synaptic remodeling and microglial activation.

    Ruiz-Pastor MJ, Sánchez-Sáez X, Kutsyr O, et al.

    Cell death & disease 2023; (14(11)):711 doi:10.1038/s41419-023-06243-8.

    PMID: 37914688
  20. 20

    The Interplay between Peripherin 2 Complex Formation and Degenerative Retinal Diseases.

    Tebbe L, Kakakhel M, Makia MS, et al.

    Cells 2020; (9(3)) doi:10.3390/cells9030784.

    PMID: 32213850
  21. 21

    Prime editing for the investigation of aberrant splicing defect associated with a pathogenic PRPH2 variant.

    Lopes da Costa B, Helms KM, Theodore K, et al.

    Molecular therapy. Nucleic acids 2025; (36(4)):102740 doi:10.1016/j.omtn.2025.102740.

    PMID: 41210588
  22. 22

    Elevating Jak-STAT signaling via SOCS3 deletion sustains photoreceptor viability and visual function in mouse models of retinitis pigmentosa.

    Wang Y, Nusinowitz S, Yang XJ

    Research square 2025; doi:10.21203/rs.3.rs-7089882/v1.

    PMID: 40671803

This page provides educational information on managing Central Areolar Choroidal Dystrophy. Always consult your ophthalmologist or genetic specialist before starting any new supplements or vision therapies.

Get notified when new evidence is published on Central areolar choroidal dystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.